Bispecific and fragmented antibodies (Fabs) have emerged as potential therapeutics that provide additional benefits, such as increase specificity and bioavailability, respectively, when compared to traditional monoclonal antibodies…
There is an increasing number of new engineered antibody formats and modalities, including monoclonal antibody fragments, bispecific antibodies (bsAbs), and single chain variable fragments…